Literature DB >> 34461297

AAV integration in human hepatocytes.

Dhwanil A Dalwadi1, Andrea Calabria2, Amita Tiyaboonchai1, Jeffrey Posey1, Willscott E Naugler3, Eugenio Montini2, Markus Grompe4.   

Abstract

Recombinant adeno-associated viral (rAAV) vectors are considered promising tools for gene therapy directed at the liver. Whereas rAAV is thought to be an episomal vector, its single-stranded DNA genome is prone to intra- and inter-molecular recombination leading to rearrangements and integration into the host cell genome. Here, we ascertained the integration frequency of rAAV in human hepatocytes transduced either ex vivo or in vivo and subsequently expanded in a mouse model of xenogeneic liver regeneration. Chromosomal rAAV integration events and vector integrity were determined using the capture-PacBio sequencing approach, a long-read next-generation sequencing method that has not previously been used for this purpose. Chromosomal integrations were found at a surprisingly high frequency of 1%-3% both in vitro and in vivo. Importantly, most of the inserted rAAV sequences were heavily rearranged and were accompanied by deletions of the host genomic sequence at the integration site.
Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FRGN; capture sequencing; genotoxicity; rAAV; random integration

Mesh:

Year:  2021        PMID: 34461297      PMCID: PMC8531150          DOI: 10.1016/j.ymthe.2021.08.031

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   12.910


  80 in total

1.  Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template.

Authors:  Blythe D Sather; Guillermo S Romano Ibarra; Karen Sommer; Gabrielle Curinga; Malika Hale; Iram F Khan; Swati Singh; Yumei Song; Kamila Gwiazda; Jaya Sahni; Jordan Jarjour; Alexander Astrakhan; Thor A Wagner; Andrew M Scharenberg; David J Rawlings
Journal:  Sci Transl Med       Date:  2015-09-30       Impact factor: 17.956

2.  Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models.

Authors:  Randy J Chandler; Mark S Sands; Charles P Venditti
Journal:  Hum Gene Ther       Date:  2017-04       Impact factor: 5.695

3.  Human gene targeting by viral vectors.

Authors:  D W Russell; R K Hirata
Journal:  Nat Genet       Date:  1998-04       Impact factor: 38.330

4.  AAV serotype 2 vectors preferentially integrate into active genes in mice.

Authors:  Hiroyuki Nakai; Eugenio Montini; Sally Fuess; Theresa A Storm; Markus Grompe; Mark A Kay
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

5.  In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.

Authors:  Dirk Grimm; Joyce S Lee; Lora Wang; Tushar Desai; Bassel Akache; Theresa A Storm; Mark A Kay
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

6.  Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas.

Authors:  Jean-Charles Nault; Shalini Datta; Sandrine Imbeaud; Andrea Franconi; Maxime Mallet; Gabrielle Couchy; Eric Letouzé; Camilla Pilati; Benjamin Verret; Jean-Frédéric Blanc; Charles Balabaud; Julien Calderaro; Alexis Laurent; Mélanie Letexier; Paulette Bioulac-Sage; Fabien Calvo; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2015-08-24       Impact factor: 38.330

7.  Adeno-associated virus finds its disease.

Authors:  David W Russell; Markus Grompe
Journal:  Nat Genet       Date:  2015-10       Impact factor: 38.330

8.  AAV vector integration sites in mouse hepatocellular carcinoma.

Authors:  Anthony Donsante; Daniel G Miller; Yi Li; Carole Vogler; Elizabeth M Brunt; David W Russell; Mark S Sands
Journal:  Science       Date:  2007-07-27       Impact factor: 47.728

Review 9.  Emerging Issues in AAV-Mediated In Vivo Gene Therapy.

Authors:  Pasqualina Colella; Giuseppe Ronzitti; Federico Mingozzi
Journal:  Mol Ther Methods Clin Dev       Date:  2017-12-01       Impact factor: 6.698

10.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

View more
  10 in total

Review 1.  Current Advances in Adeno-Associated Virus-Mediated Gene Therapy to Prevent Acquired Hearing Loss.

Authors:  Fan Wu; Kumar Sambamurti; Suhua Sha
Journal:  J Assoc Res Otolaryngol       Date:  2022-08-24

Review 2.  Evaluating the state of the science for adeno-associated virus integration: An integrated perspective.

Authors:  Denise E Sabatino; Frederic D Bushman; Randy J Chandler; Ronald G Crystal; Beverly L Davidson; Ricardo Dolmetsch; Kevin C Eggan; Guangping Gao; Irene Gil-Farina; Mark A Kay; Douglas M McCarty; Eugenio Montini; Adora Ndu; Jing Yuan
Journal:  Mol Ther       Date:  2022-06-10       Impact factor: 12.910

Review 3.  Durability of transgene expression after rAAV gene therapy.

Authors:  Manish Muhuri; Daniel I Levy; Martin Schulz; Douglas McCarty; Guangping Gao
Journal:  Mol Ther       Date:  2022-03-10       Impact factor: 12.910

4.  Preventing packaging of translatable P5-associated DNA contaminants in recombinant AAV vector preps.

Authors:  Mark A Brimble; Pei-Hsin Cheng; Stephen M Winston; Isaiah L Reeves; Aisha Souquette; Yunyu Spence; Junfang Zhou; Yong-Dong Wang; Christopher L Morton; Marcus Valentine; Paul G Thomas; Amit C Nathwani; John T Gray; Andrew M Davidoff
Journal:  Mol Ther Methods Clin Dev       Date:  2022-01-19       Impact factor: 6.698

Review 5.  Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy.

Authors:  Cedric Happi Mbakam; Gabriel Lamothe; Jacques P Tremblay
Journal:  Front Med (Lausanne)       Date:  2022-03-28

6.  A bioinformatic pipeline for simulating viral integration data.

Authors:  Suzanne Scott; Susanna Grigson; Felix Hartkopf; Claus V Hallwirth; Ian E Alexander; Denis C Bauer; Laurence O W Wilson
Journal:  Data Brief       Date:  2022-04-10

7.  Novel AAV-mediated genome editing therapy improves health and survival in a mouse model of methylmalonic acidemia.

Authors:  Shengwen Zhang; Amy Bastille; Susana Gordo; Nikhil Ramesh; Jenisha Vora; Elizabeth McCarthy; Xiaohan Zhang; Dylan Frank; Chih-Wei Ko; Carmen Wu; Noel Walsh; Shreya Amarwani; Jing Liao; Qiang Xiong; Lauren Drouin; Matthias Hebben; Kyle Chiang; B Nelson Chau
Journal:  PLoS One       Date:  2022-09-20       Impact factor: 3.752

Review 8.  Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper.

Authors:  Tong-Yuan Yang; Manuela Braun; Wibke Lembke; Fraser McBlane; John Kamerud; Stephen DeWall; Edit Tarcsa; Xiaodong Fang; Lena Hofer; Uma Kavita; Vijay V Upreti; Swati Gupta; LiNa Loo; Alison J Johnson; Rakesh Kantilal Chandode; Kay-Gunnar Stubenrauch; Maya Vinzing; Cindy Q Xia; Vibha Jawa
Journal:  Mol Ther Methods Clin Dev       Date:  2022-08-02       Impact factor: 5.849

9.  Gene therapy - are we ready now?

Authors:  Radoslaw Kaczmarek
Journal:  Haemophilia       Date:  2022-05       Impact factor: 4.263

10.  Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells.

Authors:  Samuele Ferrari; Aurelien Jacob; Daniela Cesana; Marianne Laugel; Stefano Beretta; Angelica Varesi; Giulia Unali; Anastasia Conti; Daniele Canarutto; Luisa Albano; Andrea Calabria; Valentina Vavassori; Carlo Cipriani; Maria Carmina Castiello; Simona Esposito; Chiara Brombin; Federica Cugnata; Oumeya Adjali; Eduard Ayuso; Ivan Merelli; Anna Villa; Raffaella Di Micco; Anna Kajaste-Rudnitski; Eugenio Montini; Magalie Penaud-Budloo; Luigi Naldini
Journal:  Cell Stem Cell       Date:  2022-10-06       Impact factor: 25.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.